First Patient dosed in Ph 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors June 10, 2025
Dose escalation completed in IAM1363-01 Ph 1/1b trial of IAM1363 in patients with HER2-altered cancers & brain mets / HER2 TKD mutation / HER2-amplified NSCLC June 10, 2025
Ph 1/2 trial of AVZO-023 initiated in patients with advanced or metastatic HR+/HER2- breast cancer and select other advanced solid tumors June 10, 2025
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95% PFS at four years in transplant-eligible 1L multiple myeloma patients who achieved sustained MRD negativity June 10, 2025
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in RRMM patients June 10, 2025
BMJ Publishes results from OptiTROP-Lung03 trial of sacituzumab tirumotecan (sac-TMT) vs docetaxel in patients with previously treated EGFR-mutant NSCLC June 10, 2025
Positive Topline Efficacy Results Reported from Ph 1B/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Mets (MB-107) June 10, 2025
Tempest Receives Orphan Drug Designation from the EMA for Amezalpat for the Treatment of Patients with HCC June 10, 2025
Positive opinion for Orphan Medicinal Product Designation in the EU for GLIX1 in glioma June 10, 2025
FDA Breakthrough Therapy Designation granted to Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM) June 10, 2025
FDA Orphan Drug Designation granted to MVdeltaC for the treatment of pleural mesothelioma June 10, 2025
EC Approves ADCETRIS® (brentuximab vedotin) for the Treatment of 1L Patients with Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD June 10, 2025
